In Medical Writing, a CRO creates all regulatorily relevant documents throughout the study lifecycle: the study protocol, Investigator’s Brochure (IB), Informed Consent Form (ICF), and IMPD during the start-up phase; protocol amendments, SAE narratives, and the Development Safety Update Report (DSUR) during implementation; and the Clinical Study Report (CSR), lay summaries according to EU CTR 536/2014, and publication manuscripts upon study completion. These documents determine regulatory acceptance, inspection results, and the speed of approval. Those who view document production as a downstream service risk iteration loops or even study suspension.
Key Takeaways
- Medical Writing spans three phases: start-up (protocol, IB, ICF, IMPD), implementation (amendments, SAE narratives, DSUR), and completion (CSR, lay summary, publications).
- ICH E3, ICH E6(R3), ICH E2F, and EU CTR 536/2014 define content, structure, and deadlines bindingly.
- Lay summaries must be submitted within 12 months of the end of the study, or within 6 months for pediatric studies.
- Early involvement of a CRO measurably reduces amendments, regulatory queries, and time-to-submission.
Why Medical Writing Determines Approvability
BfArM, PEI, and EMA evaluate only the submitted document, not the study itself. A classic example: the primary endpoint is defined in the protocol as an “improvement in score,” operationalized in the Statistical Analysis Plan as a “reduction,” and evaluated accordingly in the CSR. The result is a Request for Information (RfI), with each iteration loop causing a three- to six-week delay.
ICH E6(R3) and EU CTR 536/2014 define specific requirements for the protocol, ICF, IMPD, and lay summary. Integrating Medical Writing structurally into study design, data management, and regulatory affairs eliminates version conflicts at the source.
Start-up Documents: The Foundation Before the Study Begins
Before the first screening, the protocol, IB, ICF, and IMPD must be regulatorily aligned. The IMPD provides quality and safety data for the initial submission to BfArM or PEI. The IB consolidates preclinical and clinical prior knowledge. An ICF that the ethics committee rejects twice typically costs six to ten weeks in study start delays—recruitment windows that cannot be recovered in competitive indications.
Clinical Study Protocol: The Regulatory Rulebook
The protocol defines the design, endpoints, and statistical evaluation strategy bindingly and serves as a reference for all downstream documents. If Medical Writing only begins after protocol approval, an amendment cascade usually follows: unclear inclusion/exclusion criteria are refined via Amendment 1, and inconsistent endpoint definitions are corrected via Amendment 2. Every substantial amendment requires resubmission to the ethics committee and regulatory authority.
Informed Consent Form: Patient Information Under GCP
Clarity is a regulatory requirement under ICH-GCP. Ethics committees review lay comprehensibility, risk presentation, and data protection information in great detail. The target readability level is approximately a 14-year-old reading age.
Operational Documents: Documentation During the Ongoing Study
During study implementation, documents are created that directly determine data integrity, safety monitoring, and inspection readiness. SOPs ensure GCP-compliant processes across all trial sites. SAE narratives must be written in a timely manner and be consistent with the database. Gaps between narratives and the safety database are a frequent inspection finding.
DSUR: Annual Safety Reporting
The Development Safety Update Report is mandatory annually for all ongoing clinical trials according to ICH E2F. Submission occurs within 60 days of the Data Lock Point, the last day of the one-year reporting period; its annual cycle is based on the Development International Birth Date (the date of the first worldwide trial approval). It integrates data from pharmacovigilance, the protocol, and the IB.
Late DSUR submission can trigger a study suspension: a halt to patient recruitment, downtime at 20 to 50 trial sites, and a delay of the development schedule by months. This exact scenario occurs when safety reporting is handled without integrated processes.
Completion Documents: From Dataset to Regulatory Readiness
The Clinical Study Report according to ICH E3 is the central regulatory document. It brings together raw data, statistical evaluations, and conclusions into a verifiable overall presentation. A concrete example of consequences: if patient numbers differ between eCTD Module 2.5 (Clinical Overview) and Module 5 (CSR), a regulatory RfI follows. Regulatory Affairs at the sponsor must explain the discrepancy within days, while Biostatistics and Medical Writing recalculate in parallel, and the launch team postpones the planned market entry date. Per iteration loop: several weeks.
Additionally, EU CTR 536/2014 requires a lay summary for all interventional studies within 12 months of the study end, or 6 months for pediatric studies. Manuscripts for peer-reviewed journals follow ICMJE guidelines.
Those who only bring Medical Writing and Biostatistics together after database lock produce avoidable review cycles. Early coordination stabilizes the time-to-submission.
Regulatory Submission Dossiers: IMPD and eCTD
In addition to study-specific documents, a CRO also creates product-related submission documents. The IMPD consolidates quality, manufacturing, and safety data for BfArM and PEI. Every IMPD update during the study must be consistent with the protocol and IB; otherwise, an RfI follows. For electronic submissions, the eCTD structure is mandatory, and CTIS submissions under EU CTR 536/2014 require specific formats. For parallel procedures in the EU, USA, UK, and Switzerland, the respective ICH requirements apply.
Integrated Medical Writing at Mediconomics
Integrated Medical Writing prevents documentation gaps because authors, biostatistics, data management, and regulatory affairs work within the same process rather than sequentially. Specifically at Mediconomics:
- Medical Writers in the SAP Kick-off: Authors participate in the Statistical Analysis Plan kick-off, not just the CSR briefing. Endpoint wording and statistical operationalization are aligned before database lock.
- Terminology Anchors as Reference Files: Endpoint definitions, MedDRA coding, and efficacy criteria are kept in a version-controlled reference file that binds the protocol, eCRF, SAP, and CSR. Responsibility: Lead Medical Writer, approved by Biostatistics and Regulatory Affairs before the study start.
- Dual-Author Principle: Every core document undergoes a second professional author layer before QC.
- Separate QC Review by a Regulatory Affairs specialist before every submission, independent of the study team.
- Therapeutic Focus: Oncology, neurology, rare diseases, and medical device studies according to ISO 14155.
For international programs in the EU, USA, UK, Switzerland, and Denmark, we maintain parallel document versions with consistent regulatory argumentation. You receive robust documentation for BfArM, PEI, EMA, and FDA from a single source. German and English at submission level, along with CTIS and eCTD experience, are standard.
Schedule a free initial consultation.
Frequently Asked Questions
- Which documents does a CRO create in the field of Medical Writing?
- A CRO covers the entire spectrum of documents throughout the study lifecycle: start-up documents such as the Clinical Study Protocol, Investigator’s Brochure, Informed Consent Form, and IMPD; operational documents such as protocol amendments, SAE narratives, and DSUR; and completion documents such as the Clinical Study Report, lay summaries according to EU CTR 536/2014, and publication manuscripts according to ICMJE. For medical devices, Clinical Evaluation Reports according to MDR and PMCF reports are added. The specific scope depends on the regulatory framework (ICH E3, ICH E2F, EU CTR 536/2014, MDR, ISO 14155) and the target region.
- What is the difference between a CSR and a DSUR?
- The Clinical Study Report (CSR) according to ICH E3 is the final study report after the end of the study. It integrates design, methodology, statistical evaluation, and clinical interpretation into a coherent regulatory document. The Development Safety Update Report (DSUR) according to ICH E2F is a safety report to be submitted annually during ongoing development. It consolidates safety data from all ongoing studies of an investigational product and places them in the context of the IB and protocol. Thus, CSR and DSUR differ fundamentally in purpose, timing, and regulatory basis.
- What role does the IMPD play in Medical Writing?
- The Investigational Medicinal Product Dossier (IMPD) consolidates quality, manufacturing, and safety data of the investigational product and is initially submitted to BfArM or PEI before the study begins. During the study, the IMPD must be updated for relevant changes and aligned with the protocol and IB. Medical writers ensure that product-specific data, safety information, and dosage information are presented identically in all documents. Inconsistencies between the IMPD, protocol, and IB are among the most common reasons for regulatory queries.
- When should Medical Writing be involved in a clinical study?
- Involvement is advisable from the initial study design, parallel to the conception of endpoints and the statistical analysis plan. Early involvement of medical writers ensures internal consistency between the protocol, IB, ICF, and IMPD and significantly reduces subsequent protocol amendments. The eCRF review also benefits, as early coordination between Medical, Biostatistics, Data Management, and Monitoring minimizes later change requests. Those who bring in Medical Writing only toward the end of the study shift quality assurance to a phase where corrections become costly and regulatorily critical.
- What qualifications must medical writers in a CRO possess?
- Professionally sound medical writers combine medical, statistical, and regulatory knowledge. Required is a solid understanding of ICH guidelines (especially E3, E6(R3), E2F), EU CTR 536/2014, GCP fundamentals, and agency-specific requirements from BfArM, PEI, EMA, MHRA, FDA, and Swissmedic. For international submissions, experience with CTIS workflows and eCTD structure is standard. Added to this are linguistic precision in German and English as well as methodological familiarity with statistical evaluations.
